BC Week In Review | Aug 17, 2015
Company News

Merck KGaA sales and marketing update

Merck’s Merck Serono S.A. unit launched Early Embryo Viability Assessment (Eeva) test in undisclosed European countries to improve in vitro fertilization outcomes. Eeva is a non-invasive imaging test that provides quantitative information on embryo viability...
BC Week In Review | Apr 14, 2014
Company News

Auxogyn, Merck KGaA sales and marketing update

Auxogyn granted Merck's Merck Serono S.A. unit exclusive rights to commercialize Auxogyn's Early Embryo Viability Assessment (Eeva) test in Europe and Canada. Merck also has the option to extend the right to undisclosed countries and...
BC Week In Review | Oct 29, 2012
Company News

Auxogyn, Merck KGaA deal

Merck's Merck Serono S.A. unit partnered with Auxogyn to develop its Early Embryo Viability Assessment (Eeva) Test . Merck Serono will provide strategic, scientific and medical support in the development and commercialization of the test. The...
BC Week In Review | Aug 6, 2012
Clinical News

Early Embryo Viability Assessment regulatory update

Auxogyn said it received CE Mark approval for its Eeva Test to improve in vitro fertilization outcomes. Auxogyn plans to immediately launch the test in the EU. The non-invasive imaging test provides quantitative information on...
BC Week In Review | Jul 23, 2012
Clinical News

Early Embryo Viability Assessment diagnostic data

A study in 160 patients and about 1,800 embryos showed that Auxogyn's Eeva Test predicted blastocyst formation at the cleavage stage with 85% specificity and reduced the false positive rate to 15% from 43% with...
Items per page:
1 - 5 of 5